메뉴 건너뛰기




Volumn 22, Issue 10, 2014, Pages 1851-1863

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYTOKINE; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

EID: 84926152614     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.118     Document Type: Article
Times cited : (56)

References (50)
  • 1
    • 45449114994 scopus 로고    scopus 로고
    • Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded
    • Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
    • (2008) Nat Rev Microbiol , vol.6 , pp. 529-540
    • Cattaneo, R.1    Miest, T.2    Shashkova, E.V.3    Barry, M.A.4
  • 2
    • 84884594361 scopus 로고    scopus 로고
    • Optim: A randomized phase iii trial of talimogene laherparepvec (t-vec) versus subcutaneous (sc) granulocyte-macrophage colonystimulating factor (gm-csf) for the treatment (tx) of unresected state iiib/c and iv melanoma
    • (June 20 supplement
    • Hans Ingemar Andtbacka, R, Collichio, FA, Amatruda, T, Senzer, NN, Chesney, J and Delman, KA et al. (2013). OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment (tx) of unresected state IIIB/C and IV melanoma. J Clin Oncol 31 (June 20 supplement
    • (2013) J Clin Oncol , vol.31
    • Hans Ingemar Andtbacka, R.1    Collichio, F.A.2    Amatruda, T.3    Senzer, N.N.4    Chesney, J.5    Delman, K.A.6
  • 3
    • 84857225504 scopus 로고    scopus 로고
    • Replicating viral vectors for cancer therapy: Strategies to synergize with host immune responses
    • Altomonte, J and Ebert, O (2012). Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol 5: 251-259.
    • (2012) Microb Biotechnol , vol.5 , pp. 251-259
    • Altomonte, J.1    Ebert, O.2
  • 4
    • 85027956453 scopus 로고    scopus 로고
    • Thunder and lightning: Immunotherapy and oncolytic viruses collide
    • Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
    • (2011) Mol Ther , vol.19 , pp. 1008-1016
    • Melcher, A.1    Parato, K.2    Rooney, C.M.3    Bell, J.C.4
  • 5
    • 38649123395 scopus 로고    scopus 로고
    • Innate immunity tumor microenvironment and oncolytic virus therapy: Friends or foes?
    • Stanford, MM, Breitbach, CJ, Bell, JC and McFadden, G (2008). Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 10: 32-37.
    • (2008) Curr Opin Mol Ther , vol.10 , pp. 32-37
    • Stanford, M.M.1    Breitbach, C.J.2    Bell, J.C.3    McFadden, G.4
  • 7
    • 76749162295 scopus 로고    scopus 로고
    • Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for vsv therapy of b16 melanoma
    • Galivo, F, Diaz, RM, Wongthida, P, Thompson, J, Kottke, T, Barber, G et al. (2010). Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17: 158-170.
    • (2010) Gene Ther , vol.17 , pp. 158-170
    • Galivo, F.1    Diaz, R.M.2    Wongthida, P.3    Thompson, J.4    Kottke, T.5    Barber, G.6
  • 8
    • 34548062828 scopus 로고    scopus 로고
    • Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
    • Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
    • (2007) Mol Ther , vol.15 , pp. 1686-1693
    • Breitbach, C.J.1    Paterson, J.M.2    Lemay, C.G.3    Falls, T.J.4    McGuire, A.5    Parato, K.A.6
  • 9
    • 77951838524 scopus 로고    scopus 로고
    • Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
    • Kottke, T, Hall, G, Pulido, J, Diaz, RM, Thompson, J, Chong, H et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 120: 1551-1560.
    • (2010) J Clin Invest , vol.120 , pp. 1551-1560
    • Kottke, T.1    Hall, G.2    Pulido, J.3    Diaz, R.M.4    Thompson, J.5    Chong, H.6
  • 10
    • 77953172635 scopus 로고    scopus 로고
    • Type iii ifn interleukin-28 mediates the antitumor efficacy of oncolytic virus vsv in immune-competent mouse models of cancer
    • Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Pulido, J et al. (2010). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 70: 4539-4549.
    • (2010) Cancer Res , vol.70 , pp. 4539-4549
    • Wongthida, P.1    Diaz, R.M.2    Galivo, F.3    Kottke, T.4    Thompson, J.5    Pulido, J.6
  • 11
    • 34047262198 scopus 로고    scopus 로고
    • Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
    • Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
    • (2007) Cancer Res , vol.67 , pp. 2840-2848
    • Diaz, R.M.1    Galivo, F.2    Kottke, T.3    Wongthida, P.4    Qiao, J.5    Thompson, J.6
  • 12
    • 38049051428 scopus 로고    scopus 로고
    • Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive t cell therapy, oncolytic virotherapy and immunotherapy
    • Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
    • (2008) Nat Med , vol.14 , pp. 37-44
    • Qiao, J.1    Kottke, T.2    Willmon, C.3    Galivo, F.4    Wongthida, P.5    Diaz, R.M.6
  • 13
    • 40749090005 scopus 로고    scopus 로고
    • Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
    • Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269.
    • (2008) Clin Cancer Res , vol.14 , pp. 259-269
    • Qiao, J.1    Wang, H.2    Kottke, T.3    White, C.4    Twigger, K.5    Diaz, R.M.6
  • 14
    • 44849140982 scopus 로고    scopus 로고
    • Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (dearing type 3) during a phase i clinical trial
    • White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920.
    • (2008) Gene Ther , vol.15 , pp. 911-920
    • White, C.L.1    Twigger, K.R.2    Vidal, L.3    De Bono, J.S.4    Coffey, M.5    Heinemann, L.6
  • 15
    • 0036842215 scopus 로고    scopus 로고
    • Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    • Dvorak, HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
    • (2002) J Clin Oncol , vol.20 , pp. 4368-4380
    • Dvorak, H.F.1
  • 16
    • 47949089077 scopus 로고    scopus 로고
    • Vegf-targeted therapy: Mechanisms of anti-tumour activity
    • Ellis, LM and Hicklin, DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
    • (2008) Nat Rev Cancer , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 17
    • 0842311621 scopus 로고    scopus 로고
    • Vascular targeting agents as cancer therapeutics
    • Thorpe, PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
    • (2004) Clin Cancer Res , vol.10 , pp. 415-427
    • Thorpe, P.E.1
  • 18
    • 33747519945 scopus 로고    scopus 로고
    • Striking out at disseminated metastases: The systemic delivery of oncolytic viruses
    • Fisher, K (2006). Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
    • (2006) Curr Opin Mol Ther , vol.8 , pp. 301-313
    • Fisher, K.1
  • 19
    • 33646583209 scopus 로고    scopus 로고
    • Virus smuggling, tax evasion and tumor assassination
    • Harrington, K and Vile, R (2006). Virus smuggling, tax evasion and tumor assassination. Nat Med 12: 507-509.
    • (2006) Nat Med , vol.12 , pp. 507-509
    • Harrington, K.1    Vile, R.2
  • 20
    • 33748088164 scopus 로고    scopus 로고
    • Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
    • Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103: 12873-12878.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 12873-12878
    • Fulci, G.1    Breymann, L.2    Gianni, D.3    Kurozomi, K.4    Rhee, S.S.5    Yu, J.6
  • 21
    • 45749096230 scopus 로고    scopus 로고
    • Treg depletion-enhanced il-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus
    • Kottke, T, Galivo, F, Wongthida, P, Diaz, RM, Thompson, J, Jevremovic, D et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 16: 1217-1226.
    • (2008) Mol Ther , vol.16 , pp. 1217-1226
    • Kottke, T.1    Galivo, F.2    Wongthida, P.3    Diaz, R.M.4    Thompson, J.5    Jevremovic, D.6
  • 22
    • 59449108246 scopus 로고    scopus 로고
    • Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated treg modulation and interleukin-2
    • Kottke, T, Thompson, J, Diaz, RM, Pulido, J, Willmon, C, Coffey, M et al. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 15: 561-569.
    • (2009) Clin Cancer Res , vol.15 , pp. 561-569
    • Kottke, T.1    Thompson, J.2    Diaz, R.M.3    Pulido, J.4    Willmon, C.5    Coffey, M.6
  • 23
    • 80053566728 scopus 로고    scopus 로고
    • Precise scheduling of chemotherapy primes vegf-producing tumors for successful systemic oncolytic virotherapy
    • Kottke, T, Chester, J, Ilett, E, Thompson, J, Diaz, R, Coffey, M et al. (2011). Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther 19: 1802-1812.
    • (2011) Mol Ther , vol.19 , pp. 1802-1812
    • Kottke, T.1    Chester, J.2    Ilett, E.3    Thompson, J.4    Diaz, R.5    Coffey, M.6
  • 25
    • 67650375869 scopus 로고    scopus 로고
    • Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication
    • Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
    • (2009) Clin Cancer Res , vol.15 , pp. 4374-4381
    • Prestwich, R.J.1    Ilett, E.J.2    Errington, F.3    Diaz, R.M.4    Steele, L.P.5    Kottke, T.6
  • 26
    • 79955520856 scopus 로고    scopus 로고
    • Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization
    • Ilett, EJ, Bárcena, M, Errington-Mais, F, Griffin, S, Harrington, KJ, Pandha, HS et al. (2011). Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 17: 2767-2776.
    • (2011) Clin Cancer Res , vol.17 , pp. 2767-2776
    • Ilett, E.J.1    Bárcena, M.2    Errington-Mais, F.3    Griffin, S.4    Harrington, K.J.5    Pandha, H.S.6
  • 27
    • 78349299472 scopus 로고    scopus 로고
    • Reo-10: A phase i study of intravenous reovirus and docetaxel in patients with advanced cancer
    • Comins, C, Spicer, J, Protheroe, A, Roulstone, V, Twigger, K, White, CM et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572.
    • (2010) Clin Cancer Res , vol.16 , pp. 5564-5572
    • Comins, C.1    Spicer, J.2    Protheroe, A.3    Roulstone, V.4    Twigger, K.5    White, C.M.6
  • 28
    • 77953093863 scopus 로고    scopus 로고
    • Two-stage phase i dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers
    • Harrington, KJ, Karapanagiotou, EM, Roulstone, V, Twigger, KR, White, CL, Vidal, L et al. (2010). Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067-3077.
    • (2010) Clin Cancer Res , vol.16 , pp. 3067-3077
    • Harrington, K.J.1    Karapanagiotou, E.M.2    Roulstone, V.3    Twigger, K.R.4    White, C.L.5    Vidal, L.6
  • 29
    • 77953539465 scopus 로고    scopus 로고
    • Clinical trials with oncolytic reovirus: Moving beyond phase i into combinations with standard therapeutics
    • Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 21: 91-98.
    • (2010) Cytokine Growth Factor Rev , vol.21 , pp. 91-98
    • Harrington, K.J.1    Vile, R.G.2    Melcher, A.3    Chester, J.4    Pandha, H.S.5
  • 30
    • 58149252477 scopus 로고    scopus 로고
    • A phase i study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer
    • Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137.
    • (2008) Clin Cancer Res , vol.14 , pp. 7127-7137
    • Vidal, L.1    Pandha, H.S.2    Yap, T.A.3    White, C.L.4    Twigger, K.5    Vile, R.G.6
  • 32
    • 0032515141 scopus 로고    scopus 로고
    • Reovirus therapy of tumors with activated ras pathway
    • Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
    • (1998) Science , vol.282 , pp. 1332-1334
    • Coffey, M.C.1    Strong, J.E.2    Forsyth, P.A.3    Lee, P.W.4
  • 34
    • 0036376654 scopus 로고    scopus 로고
    • Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?
    • Harrington, K, Alvarez-Vallina, L, Crittenden, M, Gough, M, Chong, H, Diaz, RM et al. (2002). Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther 13: 1263-1280.
    • (2002) Hum Gene Ther , vol.13 , pp. 1263-1280
    • Harrington, K.1    Alvarez-Vallina, L.2    Crittenden, M.3    Gough, M.4    Chong, H.5    Diaz, R.M.6
  • 35
    • 43049176729 scopus 로고    scopus 로고
    • Loading of oncolytic vesicular stomatitis virus onto antigen-specific t cells enhances the efficacy of adoptive t-cell therapy of tumors
    • Qiao, J, Wang, H, Kottke, T, Diaz, RM, Willmon, C, Hudacek, A et al. (2008). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 15: 604-616.
    • (2008) Gene Ther , vol.15 , pp. 604-616
    • Qiao, J.1    Wang, H.2    Kottke, T.3    Diaz, R.M.4    Willmon, C.5    Hudacek, A.6
  • 36
    • 33947190925 scopus 로고    scopus 로고
    • Cell-based delivery of oncolytic viruses: A new strategic alliance for a biological strike against cancer
    • Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
    • (2007) Mol Ther , vol.15 , pp. 660-665
    • Power, A.T.1    Bell, J.C.2
  • 37
    • 33645239282 scopus 로고    scopus 로고
    • Synergistic antitumor effects of immune cell-viral biotherapy
    • Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
    • (2006) Science , vol.311 , pp. 1780-1784
    • Thorne, S.H.1    Negrin, R.S.2    Contag, C.H.3
  • 38
    • 84862550301 scopus 로고    scopus 로고
    • Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
    • Adair, RA, Roulstone, V, Scott, KJ, Morgan, R, Nuovo, GJ, Fuller, M et al. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 4: 138ra77.
    • (2012) Sci Transl Med , vol.4 , pp. 138ra77
    • Adair, R.A.1    Roulstone, V.2    Scott, K.J.3    Morgan, R.4    Nuovo, G.J.5    Fuller, M.6
  • 39
    • 0036813199 scopus 로고    scopus 로고
    • Gm-csf-based cancer vaccines
    • Dranoff, G (2002). GM-CSF-based cancer vaccines. Immunol Rev 188: 147-154.
    • (2002) Immunol Rev , vol.188 , pp. 147-154
    • Dranoff, G.1
  • 40
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90: 3539-3543.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3    Golumbek, P.4    Levitsky, H.5    Brose, K.6
  • 41
    • 84874937343 scopus 로고    scopus 로고
    • Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells
    • Adair, RA, Scott, KJ, Fraser, S, Errington-Mais, F, Pandha, H, Coffey, M et al. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 132: 2327-2338.
    • (2013) Int J Cancer , vol.132 , pp. 2327-2338
    • Adair, R.A.1    Scott, K.J.2    Fraser, S.3    Errington-Mais, F.4    Pandha, H.5    Coffey, M.6
  • 42
    • 3042634938 scopus 로고    scopus 로고
    • Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts
    • Babalola, CP, Nightingale, CH and Nicolau, DP (2004). Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. J Antimicrob Chemother 53: 1098-1100.
    • (2004) J Antimicrob Chemother , vol.53 , pp. 1098-1100
    • Babalola, C.P.1    Nightingale, C.H.2    Nicolau, D.P.3
  • 43
    • 4544382407 scopus 로고    scopus 로고
    • G-csf induced progenitor mobilization in mice with piga-blood cells
    • Han, B, Unsinger, J, Liu, F, Link, DC and Bessler, M (2004). G-CSF induced progenitor mobilization in mice with PIGA-blood cells. Hematol J 5: 347-352.
    • (2004) Hematol J , vol.5 , pp. 347-352
    • Han, B.1    Unsinger, J.2    Liu, F.3    Link, D.C.4    Bessler, M.5
  • 44
    • 84875225339 scopus 로고    scopus 로고
    • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia jx-594 in liver cancer
    • Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
    • (2013) Nat Med , vol.19 , pp. 329-336
    • Heo, J.1    Reid, T.2    Ruo, L.3    Breitbach, C.J.4    Rose, S.5    Bloomston, M.6
  • 45
    • 77957253429 scopus 로고    scopus 로고
    • Optim trial: A phase iii trial of an oncolytic herpes virus encoding gm-csf for unresectable stage iii or iv melanoma
    • Kaufman, HL and Bines, SD (2010). OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 6: 941-949.
    • (2010) Future Oncol , vol.6 , pp. 941-949
    • Kaufman, H.L.1    Bines, S.D.2
  • 46
    • 84880889917 scopus 로고    scopus 로고
    • Leukemia cell-rhabdovirus vaccine: Personalized immunotherapy for acute lymphoblastic leukemia
    • Conrad, DP, Tsang, J, Maclean, M, Diallo, JS, Le Boeuf, F, Lemay, CG et al. (2013). Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin Cancer Res 19: 3832-3843.
    • (2013) Clin Cancer Res , vol.19 , pp. 3832-3843
    • Conrad, D.P.1    Tsang, J.2    Maclean, M.3    Diallo, J.S.4    Le Boeuf, F.5    Lemay, C.G.6
  • 47
    • 56749164906 scopus 로고    scopus 로고
    • Use of biological therapy to enhance both virotherapy and adoptive t-cell therapy for cancer
    • Kottke, T, Diaz, RM, Kaluza, K, Pulido, J, Galivo, F, Wongthida, P et al. (2008). Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 16: 1910-1918.
    • (2008) Mol Ther , vol.16 , pp. 1910-1918
    • Kottke, T.1    Diaz, R.M.2    Kaluza, K.3    Pulido, J.4    Galivo, F.5    Wongthida, P.6
  • 48
    • 84881310761 scopus 로고    scopus 로고
    • Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse
    • Boisgerault, N, Kottke, T, Pulido, J, Thompson, J, Diaz, RM, Rommelfanger-Konkol, D et al. (2013). Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther 21: 1507-1516.
    • (2013) Mol Ther , vol.21 , pp. 1507-1516
    • Boisgerault, N.1    Kottke, T.2    Pulido, J.3    Thompson, J.4    Diaz, R.M.5    Rommelfanger-Konkol, D.6
  • 49
    • 79960125220 scopus 로고    scopus 로고
    • Broad antigenic coverage induced by vaccination with virus-based cdna libraries cures established tumors
    • Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 17: 854-859.
    • (2011) Nat Med , vol.17 , pp. 854-859
    • Kottke, T.1    Errington, F.2    Pulido, J.3    Galivo, F.4    Thompson, J.5    Wongthida, P.6
  • 50
    • 84961914156 scopus 로고    scopus 로고
    • Adoptive transfer of cytotoxic t lymphocytes targeting two different antigens limits antigen loss and tumor escape
    • Kaluza, K, Kottke, T, Diaz, RM, Rommelfanger, D, Thompson, J and Vile, RG (2012). Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 131: 844-854.
    • (2012) Hum Gene Ther , vol.131 , pp. 844-854
    • Kaluza, K.1    Kottke, T.2    Diaz, R.M.3    Rommelfanger, D.4    Thompson, J.5    Vile, R.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.